Evidence map›Paper›PMID 10982326›Full record

ArticleJournal of virology2000

Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs.

L Yuan, A Geyer, D C Hodgins, Z Fan, Y Qian, K O Chang, S E Crawford, V Parreño, L A Ward, M K Estes and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 88 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Development of a Bacillus subtilis-based rotavirus vaccine.Clinical and vaccine immunology : CVI · 2010
    Article
  15. Article
  16. Article
  17. Article
  18. Why does the world need another rotavirus vaccine?Therapeutics and clinical risk management · 2008
    Article
  19. Review
  20. Preparation of recombinant vaccines.Biotechnology annual review · 2007
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

L YuanFood Animal Health Research Program, Department of Veterinary Preventive Medicine, Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, Ohio 44691-4096, USA.
A Geyer
D C Hodgins
Z Fan
Y Qian
K O Chang
S E Crawford
V Parreño
L A Ward
M K Estes
M E Conner
L J Saif
The Ohio State University · USBaylor College of Medicine · USVeterans Health Administration · US

Funding

ENHANCING THE IMMUNOGENICITY OF HUMAN ROTAVIRUS VACCINESR01AI033561 · NIAID · OHIO STATE UNIVERSITY · PI SAIF, LINDA J. · 1992 to 2006
$945k
IMMUNE RESPONSE TO ROTAVIRUS--MATERNAL ANTIBODIESR01AI037111 · NIAID · OHIO STATE UNIVERSITY · PI SAIF, LINDA J. · 1994 to 2003
$936k
NIAID NIH HHS R01 AI033561NIAID NIH HHS R01 AI037111NIAID NIH HHS R01AI33561NIAID NIH HHS R01AI37111
6 · The paper itself

Abstract

We investigated the immunogenicity of recombinant double-layered rotavirus-like particle (2/6-VLPs) vaccines derived from simian SA11 or human (VP6) Wa and bovine RF (VP2) rotavirus strains. The 2/6-VLPs were administered to gnotobiotic pigs intranasally (i.n.) with a mutant Escherichia coli heat-labile toxin, LT-R192G (mLT), as mucosal adjuvant. Pigs were challenged with virulent Wa (P1A[8],G1) human rotavirus at postinoculation day (PID) 21 (two-dose VLP regimen) or 28 (three-dose VLP regimen). In vivo antigen-activated antibody-secreting cells (ASC) (effector B cells) and in vitro antigen-reactivated ASC (derived from memory B cells) from intestinal and systemic lymphoid tissues (duodenum, ileum, mesenteric lymph nodes [MLN], spleen, peripheral blood lymphocytes [PBL], and bone marrow lymphocytes) collected at selected times were quantitated by enzyme-linked immunospot assays. Rotavirus-specific immunoglobulin M (IgM), IgA, and IgG ASC and memory B-cell responses were detected by PID 21 or 28 in intestinal and systemic lymphoid tissues after i.n. inoculation with two or three doses of 2/6-VLPs with or without mLT. Greater mean numbers of virus-specific ASC and memory B cells in all tissues prechallenge were induced in pigs inoculated with two doses of SA11 2/6-VLPs plus mLT compared to SA11 2/6-VLPs without mLT. After challenge, anamnestic IgA and IgG ASC and memory B-cell responses were detected in intestinal lymphoid tissues of all VLP-inoculated groups, but serum virus-neutralizing antibody titers were not significantly enhanced compared to the challenged controls. Pigs inoculated with Wa-RF 2/6-VLPs (with or without mLT) developed higher anamnestic IgA and IgG ASC responses in ileum after challenge compared to pigs inoculated with SA11 2/6-VLPs (with or without mLT). Three doses of SA 11 2/6-VLP plus mLT induced the highest mean numbers of IgG memory B cells in MLN, spleen, and PBL among all groups postchallenge. However, no significant protection against diarrhea or virus shedding was evident in any of the 2/6-VLP (with or without mLT)-inoculated pigs after challenge with virulent Wa human rotavirus. These results indicate that 2/6-VLP vaccines are immunogenic in gnotobiotic pigs when inoculated i.n. and that the adjuvant mLT enhanced their immunogenicity. However, i.n. inoculation of gnotobiotic pigs with 2/6-VLPs did not confer protection against human rotavirus challenge.

Indexed as

Escherichia coli ProteinsImmunity, InnateAnimalsAntibody FormationBacterial ToxinsB-LymphocytesCattleEnterotoxinsEscherichia coli InfectionsGerm-Free LifeHumansMutationRotavirusRotavirus InfectionsSwineVirionBacterial ToxinsEnterotoxinsEscherichia coli Proteinsheat-labile enterotoxin, E coli

Identifiers

PMID10982326
PMCPMC102078
OpenAlexW2143084803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.